Pathological complete response of renal cell carcinoma with vena cava tumor thrombus to neoadjuvant TKI/IO combination therapy

Takuto Hara; Tomoaki Terakawa; Toshiki Hyodo; Naoe Jinbo; Yuzo Nakano; Masato Fujisawa

doi:10.1016/j.eucr.2021.101800

Pathological complete response of renal cell carcinoma with vena cava tumor thrombus to neoadjuvant TKI/IO combination therapy

Urol Case Rep. 2021 Aug 9:39:101800. doi: 10.1016/j.eucr.2021.101800. eCollection 2021 Nov.

Authors

Takuto Hara¹, Tomoaki Terakawa¹, Toshiki Hyodo², Naoe Jinbo², Yuzo Nakano¹, Masato Fujisawa¹

Affiliations

¹ Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
² Division of Diagnostic Pathology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.

Abstract

A 79-year-old female was diagnosed with a right renal tumor with a level II tumor thrombus of the vena cava. presurgical therapy was initiated with a combination of avelumab and axitinib for 3 monthes. Then, she underwent nephrectomy and thrombectomy. Histologically, the primary tumor and tumor thrombus had no viable cells, indicating that pathological complete response was achieved with presurgical tyrosine kinase inhibitor/Immuno-oncology combination therapy. An immunohistological xamination showed very strong staining for tumor-infiltrating lymphocytes in the embolized area of the tumor, with CD8 predominating over CD4.

Keywords: Nephrectomy; Presurgical therapy; Renal cell carcinoma; TKI/IO combination Therapy.

Publication types

Case Reports